FDA advisory committee approves Selzentry.
D026683:Advisory Committees; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000627:therapeutic use*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D000077592:Maraviroc; D019713:Receptors, CCR5 / Q000378:metabolism; D014230:Triazoles / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D019713:Receptors, CCR5; D014230:Triazoles; D000077592:Maraviroc